The Clinical Value of Metagenomic Next-Generation Sequencing in Pneumocystis jirovecii Pneumonia
Meng-Qi Huang,Ting-Ting Zheng,Xiao-Rong Wang,Fei Xiang
DOI: https://doi.org/10.2147/idr.s444571
2024-01-10
Infection and Drug Resistance
Abstract:Meng-Qi Huang, &ast Ting-Ting Zheng, &ast Xiao-Rong Wang, Fei Xiang Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fei Xiang, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei Province, 430022, People's Republic of China, Tel +86-18971550171, Fax +86-27-85726114, Email ; Background: The incidence of Pneumocystis jirovecii pneumonia (PJP) is increasing. Methods: 108 patients were analysed retrospectively at the Wuhan Union Hospital. The patients were classified into the PJP group or the P. jirovecii colonisation (PJC) group based on clinical diagnosis. Clinical data included demographics, laboratory examinations, treatment, and outcomes. Results: A notable difference in the fungal load was seen between two groups, with median reads of 3215.79 vs. 5.61 in two groups, respectively ( P < 0.001). The optimal threshold value for discriminating P. jirovecii infection between colonisation for mNGS was six, and serum (1,3)-β-D-glucan (BDG) was 47.6 pg/mL. Besides, the positive detection rate of mNGS for co-pathogens in PJP patients was significantly higher than that of culture (88.16% vs. 22.37%, P < 0.0001). Epstein-Barr virus and cytomegalovirus were the most common pathogens of co-infection in PJP patients. The antibiotic therapy in PJP patients was adjusted according to the mNGS results, of which seventeen (22.37%) were downgraded, 38 (50.0%) patients were upgraded, and 21 (27.63%) were unchanged. And almost all patients showed significant improvement in C-reactive protein. Conclusion: mNGS is a promising and valuable technique with good performance for differentiating P. jirovecii infection and colonisation, the detection of pathogens, and antibiotic treatment. Keywords: Pneumocystis jirovecii pneumonia, Pneumocystis jirovecii , clinical value, metagenomic next-generation sequencing, non-HIV P. jirovecii is a common fungal pathogen that commonly causes opportunistic lung infections in individuals with impaired immune systems. 1 PJP was initially considered a human immunodeficiency virus (HIV)-related disease associated with the organism's T-cell immunity. The incidence of PJP among HIV patients has gradually declined due to the implementation of highly effective antiretroviral therapy and chemoprophylaxis for HIV, especially in countries and regions where routine HIV testing and timely treatment are available. 2,3 Meanwhile, the prevalence of PJP has increased in non-acquired immunodeficiency syndrome (AIDS) groups with a combination of immunocompromise, owing to the growing proportion of immunosuppressive drugs and corticosteroids applied in clinical practice and the parallel increase in transplant patients with advances in medical technology. 4 Concerningly, patients with non-AIDS combined with immunocompromised PJP usually have a poor prognosis as a result of their severe symptoms, acute disease course, and rapid progression. 5 Furthermore, the mortality rate increases as well. Hematologic tumours, autoimmune disorders, and taking corticosteroids or immunosuppressants for a long time are risk factors for PJP. Fever, a dry cough, hypoxemia, and dyspnea are the typical clinical symptoms of PJP. Diffuse ground glass shadows are considered the characteristic images of the lungs in PJP patients, with changes such as cysts, solids, nodules, and spontaneous pneumothorax followed by others. 7 Trimethoprim-sulfamethoxazole (TMP-SMZ) is currently the preferred first-line prophylactic and therapeutic regimen. 8 Detection of P. jirovecii mostly relies on the staining of clinical specimens with Gomori methenamine silver (GMS) stains and finding characteristic cysts or their trophic forms under the microscope. Thus, the microbiological diagnosis was limited. Meanwhile, delayed diagnosis means a lag in treatment and worsening of symptoms. The insufficient detection performance of traditional methods has promoted the speedy development of modern diagnostic methods. The serum BDG assay and the serum level of S-adenosylmethionine (SAM) are regarded as supplements for comprehensive diagnosis. 9 Real-time quantitative fluorescent PCR assays can detect extremely low fungal loads, 10 but they have not been widely validated and used. Recent studies have also been conducted to distinguish -Abstract Truncated-
pharmacology & pharmacy,infectious diseases